Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 26, Issue 10, Pages 2107-2113
Publisher
Oxford University Press (OUP)
Online
2015-07-28
DOI
10.1093/annonc/mdv315
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Alternate sunitinib schedules in patients with metastatic renal cell carcinoma
- (2015) S. Kalra et al. ANNALS OF ONCOLOGY
- A 2weeks on and 1week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma
- (2014) Y.G. Najjar et al. EUROPEAN JOURNAL OF CANCER
- Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma--Comparison to Standard Dosing Schedule of 4-Weeks-on and 2-Weeks-off
- (2014) T. Kondo et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Clinical biomarkers of response in advanced renal cell carcinoma
- (2013) A. Ravaud et al. ANNALS OF ONCOLOGY
- GOAL: An inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer
- (2013) Sergio Bracarda et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Optimal Management of Metastatic Renal Cell Carcinoma: Current Status
- (2013) Bernard Escudier et al. DRUGS
- Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules
- (2013) Bradley J. Atkinson et al. JOURNAL OF UROLOGY
- Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature
- (2013) Georg A. Bjarnason et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Randomized controlled trial versus comparative cohort study in verifying the therapeutic role of lymphadenectomy in endometrial cancer
- (2012) Yukiharu Todo et al. International Journal of Clinical Oncology
- Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single-center experience with 31 patients
- (2012) Bruno Neri et al. INTERNATIONAL JOURNAL OF UROLOGY
- Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
- (2012) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment-Associated Adverse Event Management in the Advanced Renal Cell Carcinoma Patient Treated with Targeted Therapies
- (2011) A. Ravaud ONCOLOGIST
- From Randomized Controlled Trials to Observational Studies
- (2009) Stuart L. Silverman AMERICAN JOURNAL OF MEDICINE
- How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents
- (2009) A. Ravaud ANNALS OF ONCOLOGY
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
- (2009) Brett E. Houk et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started